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Abstract
Introduction: Ondansetron, a 5-hydroxytryptamine3 receptor antagonist widely used in the prevention
and treatment of chemotherapy-induced nausea and vomiting, is associated with various unusual adverse
drug reactions. In this paper, we describe a hypersensitivity reaction to a single intravenous dose of
ondansetron.
Case presentation: A 19-year-old woman presented to the emergency department of our institute with
3–4 episodes of nausea, vomiting and epigastric distress. She had a diagnosis of polycystic ovarian disease
and had been on treatment with cyproterone acetate 2 mg, ethinyl estradiol 0.035 mg, finasteride 5 mg
and metformin 500 mg for a month. She had been taking oral roxithromycin 500 mg per day for the past
3 days for treatment of a mild upper respiratory tract infection. She also occasionally took rabeprazole 10
mg for gastritis which had worsened after treatment with roxithromycin. She was treated with a single 4
mg dose of ondansetron intravenously. She immediately developed urticaria, which was treated with
intravenous dexamethasone 4 mg and chlorpheniramine maleate 20 mg. The reaction abated within a few
minutes and she was discharged within an hour. She was asymptomatic at 72 hours of follow-up.
She had no history of ondansetron exposure, or drug or food allergies. On the Naranjo's causality
assessment scale, the adverse event was 6 indicating a "probable" reaction to ondansetron.
Conclusion:  5-hydroxytryptamine3 receptor antagonists have been associated with life-threatening
adverse reactions such as hypotension, seizures and anaphylaxis. The wide availability of these drugs in
India has promoted their off label use in the treatment of gastritis, migraine and so on. Our case represents
an off label use in a patient who could have been treated with a safer drug.
Some authors have suggested that anaphylaxis may be a class effect while others think it may be drug
specific. In our case, the reaction could be either anaphylaxis or anaphylactoid, but the latter seems more
likely given the history of absence of prior sensitization. Other components of the drug, such as solvent,
also need to be considered as a cause of this reaction. Considering all of the existing evidence, we need
to be more cautious while using ondansetron and also to be aware of the various unusual side effects,
especially when used in an out-of-hospital set-up.
Our case report underscores the importance of physicians judiciously using the drug, particularly in the 
outpatient setting so as to reduce the incidence of avoidable adverse drug reactions.
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Introduction
Ondansetron is a 5-hydroxytryptamine3 (5-HT3) receptor
antagonist widely used in the prevention and treatment of
chemotherapy-induced nausea and vomiting, especially
caused by highly emetogenic drugs such as cisplatin, and
is considered a gold standard for this purpose [1]. It may
also be used in the prevention and treatment of radiation
induced nausea and vomiting as well as post-operative
nausea and vomiting. Commonly seen side effects include
constipation or diarrhea, headache and dizziness. All 5-
HT3  receptor antagonists have been associated with
asymptomatic electrocardiogram changes, such as prolon-
gation of the PT and QTc intervals and certain arrhythmias
[2]. The clinical significance of these side effects is
unknown. Hypersensitivity to ondansetron is a rare side
effect. In this paper, the authors describe a case of hyper-
sensitivity to a single intravenous injection of ondanset-
ron.
Case presentation
A 19-year-old female patient visited the emergency
department (ED) of a tertiary referral center with 3–4 epi-
sodes of nausea, vomiting and epigastric distress. She had
been diagnosed with polycystic ovarian disease (PCOD)
and had been on treatment with cyproterone acetate 2 mg,
ethinyl estradiol 0.035 mg, finasteride 5 mg and met-
formin 500 mg for one month. The patient had also been
taking oral roxithromycin 500 mg per day for the past 3
days for treatment of a mild upper respiratory tract infec-
tion. The patient also occasionally took a single dose rab-
eprazole 10 mg for gastritis. The gastritis had worsened
after treatment with roxithromycin which was the cause of
her visit to the ED. She was treated with a single 4 mg dose
of ondansetron intravenously. Within a few seconds, the
patient developed redness and wheals around the injec-
tion site along with urticaria. There was no hypotension or
bronchospasm. She was immediately treated with intrave-
nous dexamethasone 4 mg and chlorpheniramine
maleate 20 mg. The reaction abated within a few minutes.
The patient did not complain of any other symptoms and
was discharged after an hour of observation. She was
asymptomatic at 72 hours of follow-up.
On further history taking, the patient gave no previous
history of use of ondansetron or other 5-HT3 antagonist
exposure, and no drug or food allergies. There was no his-
tory of a similar episode in the past. She gave no personal
or family history of atopy, asthma or bronchitis. On the
Naranjo's causality assessment scale, the adverse event
was 6 indicating a "probable" reaction to ondansetron [3].
Discussion
5-HT3 receptor antagonists such as ondansetron, tropiset-
ron, granisetron and palonosetron are generally associ-
ated with a wide safety margin and are widely used in
cancer chemotherapy. There are, however, reports of life-
threatening adverse events such as generalized tonic
clonic seizures, hypotension [4], chest pain and dystonia
[5]. To date, all anaphylaxis and anaphylactoid reactions
induced by ondansetron have been in patients receiving
the drug for cancer chemotherapy. This has prompted
some authors to suggest that the drug's use should be
restricted [6]. In the Indian market, the drugs have a wide
availability with over 43 different brands. [2]. The wide
availability of this class of drug has promoted the off label
use of these drugs, such as in the treatment of antimalar-
ial-induced vomiting, gastritis, migraines and other eme-
togenic conditions. The present case also represents the
off label use of the drug in a patient who could have prob-
ably received safer medication such as domperidone or
metoclopramide.
Some authors have suggested that anaphylaxis may be a
class effect [7], while others think it may be drug specific
[8]. Ondansetron and tropisetron share an indole hetero-
cycle, while granisetron does not. This may justify the
reports contradicting anaphylaxis as a class effect. While
anaphylaxis is IgE mediated, anaphylactoid reactions are
non-immune mediated. We did not determine IgE levels
in this patient. A skin test was also not done, given the
serious nature of the reaction. Thus the reaction could
have been either anaphylaxis or anaphylactoid, but the
latter seems more likely given the history of absence of
prior sensitization. In 1993, Chen et al. reported that a
total of 24 cases of varying manifestations of anaphylaxis
or anaphylactoid reactions were reported to the United
States Food and Drug Administration [9].
In the wake of the above evidence, and the increasing
availability and off label use of ondansetron and other 5-
HT3 receptor antagonists, we need to be more cautious
while using this drug and also to be aware of the various
unusual side effects, especially when used in an out-of-
hospital set-up where prompt treatment of the reaction
may not be possible. Our case report underscores the
importance of physicians judiciously using the drug so as
to reduce the incidence of similar avoidable adverse drug
reactions.
Conclusion
We emphasize the need to be judicious in the use of
ondansetron and five other HT3 receptor antagonists due
to their association with various unusual and life-threat-
ening reactions. We also caution against the off label use
of the drugs, especially in an out-of-hospital set-up.
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